BELLUS Health Inc. (BLU) – Buy Target – $11.50 or better

Buy Target – $11.50 or better
Sell Target – TradersPro Sell Signal

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer’s disease. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada

 
Trending Ideas

Featured Stocks On The Move

Featured Stocks On The Move